Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population

BMC Cancer

Kim E Innes⁴  Jeffrey H Wimsatt³  Stephanie Frisbee¹  Alan M Ducatman² 

[1] Department of Health Policy, Management and Leadership, West Virginia University School of Public Health, PO Box 9190, Morgantown, WV 26506-9190, USA

[2] Department of Medicine and Cancer Center, West Virginia University School of Medicine, Morgantown, WV 26506-9190, USA

[3] Department of Medicine, West Virginia University School of Medicine, Morgantown, WV 26506-9190, USA

[4] University of Virginia Health System, Charlottesville, Virginia 22908-0782, USA

关键词: Inflammation;    Body mass index;    Gender;    Peroxisome proliferator-activated receptors (PPARs);    Perfluoroalkyl acids;    Perfluorocarbons;    Perfluorooctane sulfonate (PFOS);    Perfluorooctanoate (PFOA);    Colon cancer;    Colorectal cancer epidemiology;   

Others  :  859111
DOI  :  10.1186/1471-2407-14-45

 received in 2012-06-25, accepted in 2013-11-07,  发布年份 2014

【 摘 要 】

Background

Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are persistent environmental contaminants that affect metabolic regulation, inflammation, and other factors implicated in the development and progression of colorectal cancer (CRC). However, the link between these compounds and CRC remains unknown. In this cross-sectional study, we investigated the association of CRC diagnosis to PFOA and PFOS blood levels in a large Appalachian population.

Methods

Participants were 47,359 adults ≥ 21 years of age and residing in six PFOA-contaminated water districts in the mid-Ohio Valley (N = 47,151 cancer-free adults, 208 cases of primary CRC). All participants completed a comprehensive health survey between 2005 and 2006; serum levels of PFOA, PFOS, and a range of other blood markers were also measured. Medical history was assessed via self report and cancer diagnosis confirmed via chart review.

Results

CRC showed a strong inverse, dose–response association with PFOS serum levels (odds ratio (OR) adjusted for potential confounders = 0.2, 95% confidence interval (CI) 0.2,0.3) for highest vs. lowest quartile of PFOS, P-trend < 0.00001) and a significant, but more modest inverse association with PFOA (adjusted OR = 0.6 (CI 0.4, 0.9) for highest vs. lowest quartile, P-trend = 0.001). These inverse associations were stronger in those diagnosed within the previous 6 years and resident in the same water district for a minimum of 10–15 years preceding assessment. The relationship between PFOA and CRC was also more pronounced in men and leaner adults, and showed a stronger linear trend at lower exposure levels.

Conclusions

In this large cross-sectional study, we found a strong, inverse association between PFOS and likelihood of CRC diagnosis and a significant, although more modest inverse association between PFOA and CRC. If confirmed in prospective investigations, these findings may aid in identifying new strategies for CRC prevention and treatment and inform future studies regarding mechanisms underlying CRC pathogenesis.

【 授权许可】

   
2014 Innes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]U.S. Cancer Statistics Working Group, United States Cancer Statistics: 1999–2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010.
• [2]Edwards B, Ward E, Kohler B, et al.: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer Res 2010, 116(3):544-573.
• [3]Hao YP, Jemal A, Zhang XY, Ward EM: Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995–2004 (United States). Cancer Cause Control 2009, 20(10):1855-1863.
• [4]Kojima M, Wakai K, Tokudome S, et al.: Bowel movement frequency and risk of colorectal cancer in a large cohort study of Japanese men and women. Br J Cancer 2004, 90(7):1397-1401.
• [5]Watanabe T, Nakaya N, Kurashima K, Kuriyama S, Tsubono Y, Tsuji I: Constipation, laxative use and risk of colorectal cancer: The Miyagi Cohort Study. Eur J Cancer 2004, 40(14):2109-2115.
• [6]Cuzick J, Otto F, Baron JA, et al.: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10(5):501-507.
• [7]Thun MJ, Henley SJ, Patrono C: Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. J Natl Cancer Inst 2002, 94(No. 4):252-266.
• [8]Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH: Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005, 21(4):321-339.
• [9]Harris RE, Beebe-Donk J, Doss H, Burr DD: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005, 13(4):559-583.
• [10]Hatton JL, Yee LD: Clinical Use of PPARγ Ligands in Cancer. PPAR Research. 2008. doi:10.1155/2008/159415:1–13
• [11]Peters JM, Shah YM, Gonzalez FJ: The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012, 12:181-195.
• [12]Weyer PJ, Cerhan JR, Kross BC, et al.: Municipal drinking water nitrate level and cancer risk in older women: The Iowa Women's Health Study. Epidemiology 2001, 12(3):327-338.
• [13]Doyle TJ, Zheng W, Cerhan JR, et al.: The association of drinking water source and chlorination by-products with cancer incidence among postmenopausal women in Iowa: A prospective cohort study. Am J Public Health 1997, 87(7):1168-1176.
• [14]Grice MM, Alexander BH, Hoffbeck R, Kampa DM: Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med 2007, 49(7):722-729.
• [15]Olsen GW, Burlew MM, Marshall JC, Burris JM, Mandel JH: Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facility. J Occup Environ Med 2004, 46(8):837-846.
• [16]Corsini E, Sangiovanni E, Avogadro A, et al.: In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol Appl Pharm 2012, 258(2):248-255.
• [17]Mollenhauer MA, Bradshaw SG, Fair PA, McGuinn WD, Peden-Adams MM: Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice. J Environ Sci Health A Tox Hazard Subst Environ Eng 2011, 46(2):97-108.
• [18]DeWitt JC, Shnyra A, Badr MZ, et al.: Immunotoxicity of Perfluorooctanoic Acid and Perfluorooctane Sulfonate and the Role of Peroxisome Proliferator-Activated Receptor Alpha. Crit Rev Toxicol 2009, 39(1):76-94.
• [19]Steenland K, Tinker S, Shankar A, Ducatman A: Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with Uric Acid among Adults with Elevated Community Exposure to PFOA. Environ Health Perspect 2010, 118:229-233.
• [20]Frisbee SJ, Brooks AP Jr, Maher A, et al.: The C8 Health Project: Design, Methods, and Participants. Environ Health Perspect 2009, 117(12):1873-1882.
• [21]Bartell S, Calafat A, Lyu C, Kato K, Ryan P, Steenland K: Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect 2010, 118(2):222-228.
• [22]Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V: Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol 2009, 170(10):1268-1278.
• [23]FDA U: Guidance for industry: bioanalytical method validation. Rockville, MD: CDER, ed.; 2001.
• [24]Calafat AM, Wong L-Y, Kuklenyik Z, Reidy JA, Needham LL: Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and Comparisons with NHANES 1999–2000. Environ Health Perspect 2007, 115(11):1596-1602.
• [25]Nelson JW, Hatch EE, Webster TF: Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 2010, 118(2):197-202.
• [26]Eriksen KT, Sorensen M, McLaughlin JK, et al.: Perfluorooctanoate and Perfluorooctanesulfonate Plasma Levels and Risk of Cancer in the General Danish Population. J Natl Cancer Inst 2009, 101(8):605-609.
• [27]Vassiliadou I, Costopoulou D, Ferderigou A, Leondiadis L: Levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in blood samples from different groups of adults living in Greece. Chemosphere 2010, 80(10):1199-1206.
• [28]Franceschi S, Gallus S, Talamini R, Tavani A, Negri E, La Vecchia C: Menopause and colorectal cancer. Br J Cancer 2000, 82(11):1860-1862.
• [29]Peters RK, Pike MC, Chang WW, Mack TM: Reproductive factors and colon cancers. Br J Cancer 1990, 61(5):741-748.
• [30]Wu AH, Paganini-Hill A, Ross RK, Henderson BE: Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 1987, 55(6):687-694.
• [31]van Wayenburg CA, van der Schouw YT, van Noord PA, Peeters PH: Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort. Epidemiology 2000, 11(3):304-308.
• [32]Wu-Williams AH, Lee M, Whittemore AS, et al.: Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991, 51(9):2307-2311.
• [33]Martinez ME, Grodstein F, Giovannucci E, et al.: A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidem Biomar 1997, 6(1):1-5.
• [34]Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S: Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case–control study in the United States. Cancer Causes Control 1997, 8(2):146-158.
• [35]Simon MS, Rosenberg CA, Rodabough RJ, et al.: Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 2012, 22(1):17-27.
• [36]Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352(21):2184-2192.
• [37]Bonovas S, Filioussi K, Flordellis CS, Sitaras NM: Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007, 25(23):3462-3468.
• [38]Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006, 98(1):69-72.
• [39]Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case–control study. Gastroenterology 2007, 133(2):393-402.
• [40]Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S: Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007, 115(1):27-33.
• [41]Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN: Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009, 104(12):3015-3023.
• [42]Zafar SY, Abernethy AP, Abbott DH, et al.: Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. Bmc Cancer 2008, 8(345):1-9. doi:10.1186/1471-2407-8-345
• [43]Yancik R, Wesley MN, Ries LAG, et al.: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients - A population-based study. Cancer 1998, 82(11):2123-2134.
• [44]Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. Int J Epidemiol 2007, 36(5):951-957.
• [45]Stocks T, Lukanova A, Johansson M, et al.: Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008, 32(2):304-314.
• [46]Giovannucci E: Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007, 86(3):s836-842.
• [47]Larsson SC, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97(22):1679-1687.
• [48]Pischon T, Lahmann PH, Boeing H, et al.: Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 2006, 98(13):920-931.
• [49]Seals R, Bartell SM, Steenland K: Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community. Environ Health Perspect 2011, 119(1):119-124.
• [50]Olsen GW, Burris JM, Ehresman DJ, et al.: Half-life serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007, 115(9):1298-1305.
• [51]Lewis SJ, Heaton KW: The metabolic consequences of slow colonic transit. Am J Gastroenterol 1999, 94(8):2010-2016.
• [52]Kudo N, Kawashima Y: Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci 2003, 28(2):49-57.
• [53]Jandacek RJ, Tso P: Enterohepatic circulation of organochlorine compounds: a site for nutritional intervention. J Nutr Biochem 2007, 18(3):163-167.
• [54]Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J: Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007, 99(2):366-394.
• [55]Dong GH, Zhang YH, Zheng L, Liang ZF, Jin YH, He QC: Subchronic effects of perfluorooctanesulfonate exposure on inflammation in adult male C57BL/6 mice. Environ Toxicol 2012, 27(5):285-296.
• [56]Taylor BK, Kriedt C, Nagalingam S, Dadia N, Badr M: Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm Res 2005, 54(6):235-242.
• [57]Brieger A, Bienefeld N, Hasan R, Goerlich R, Haase H: Impact of perfluorooctanesulfonate and perfluorooctanoic acid on human peripheral leukocytes. Toxicol In Vitro 2011, 25(4):960-968.
• [58]Vanden Heuvel J, Thompson J, Frame S, Gillies P: Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci 2006, 92(2):476-489.
• [59]Mohapatra SK, Guri AJ, Climent M, et al.: Immunoregulatory Actions of Epithelial Cell PPAR γ at the Colonic Mucosa of Mice with Experimental Inflammatory Bowel Disease. PLoS ONE 2010, 5(4):e10215.
• [60]Nakagawa T, Ramdhan DH, Tanaka N, et al.: Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARalpha in mice. Arch Toxicol 2012, 86(1):63-74.
• [61]Giaginis C, Tsantili-Kakoulidou A, Theocharis S: Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007, 21(3):231-244.
• [62]Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116(3):571-580.
• [63]Martinasso G, Oraldi M, Trombetta A, et al.: Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines. PPAR Res 2007, 2007:93416.
• [64]Clark RB: The role of PPARs in inflammation and immunity. J Leukoc Biol 2002, 71(3):388-400.
• [65]Giaginis C, Giagini A, Theocharis S: Peroxisome proliferator-activated receptor-y (PPAR-y) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res 2009, 60:160-169.
• [66]Martin H: Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res 2010, 690(1–2):57-63.
• [67]Jackson L, Wahli W, Michalik L, et al.: Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 2003, 52(9):1317-1322.
• [68]Mutoh M, Niho N, Wakabayashi K: Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006, 387(4):381-385.
• [69]Volkel W, Genzel-Boroviczeny O, Demmelmair H, et al.: Perfluorooctane sulphonate (PFOS) and perfluorooctanoic acid (PFOA) in human breast milk: results of a pilot study. Int J Hyg Environ Health 2008, 211(3–4):440-446.
• [70]Komizu Y, Ueoka H, Goto K, Ueoka R: Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis. Int J Nanomedicine 2011, 6:1913-1920.
• [71]Fayad W, Rickardson L, Haglund C, et al.: Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties. Chem Biol Drug Des 2011, 78(4):547-557.